Abstract:With the epidemic of human obesity, dietary fats have increasingly become a focal point of biomedical research. Epidemiological studies indicate that high-fat diets (HFDs), especially those rich in long-chain saturated fatty acids (e.g., Western Diet, National Health Examination survey; NHANES 'What We Eat in America' report) have multi-organ pro-inflammatory effects. Experimental studies have confirmed some of these disease associations, and have begun to elaborate mechanisms of disease induction. However, many of the observed effects from epidemiological studies appear to be an over-simplification of the mechanistic complexity that depends on dynamic interactions between the host, the particular fatty acid, and the rather personalized genetics and variability of the gut microbiota. Of interest, experimental studies have shown that certain saturated fats (e.g., lauric and myristic fatty acid-rich coconut oil) could exert the opposite effect; that is, desirable anti-inflammatory and protective mechanisms promoting gut health by unanticipated pathways. Owing to the experimental advantages of laboratory animals for the study of mechanisms under well-controlled dietary settings, we focus this review on the current understanding of how dietary fatty acids impact intestinal biology. We center this discussion on studies from mice and rats, with validation in cell culture systems or human studies. We provide a scoping overview of the most studied diseases mechanisms associated with the induction or prevention of Inflammatory Bowel Disease in rodent models relevant to Crohn's Disease and Ulcerative Colitis after feeding either high-fat diet (HFD) or feed containing specific fatty acid or other target dietary molecule. Finally, we provide a general outlook on areas that have been largely or scarcely studied, and assess the effects of HFDs on acute and chronic forms of intestinal inflammation.

Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions

Lipopolysaccharides Derived from Gram-Negative Bacterial Pool of Human Gut Microbiota Promote Inflammation and Obesity Development

The Effect of Enteric-Derived Lipopolysaccharides on Obesity

Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice

Metabolic endotoxemia is dictated by the type of lipopolysaccharide

From the Gut to Neurodegeneration

The impact of metabolites derived from the gut microbiota on immune regulation and diseases

Metabolic Endotoxemia Initiates Obesity and Insulin Resistance

Metabolic endotoxemia promotes neuroinflammation after focal cerebral ischemia

Regulation of Intestinal Inflammation by Dietary Fats

The Role of the Gut Microbiota in Energy Metabolism and Metabolic Disease

Gut microbial metabolite short-chain fatty acids and obesity

Gut microbial metabolites in obesity, NAFLD and T2DM

Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship

Dietary Gut Microbial Metabolites, Short-chain Fatty Acids, and Host Metabolic Regulation

Lactobacillus pentosus S-PT84 Prevents Low-Grade Chronic Inflammation-Associated Metabolic Disorders in a Lipopolysaccharide and High-Fat Diet C57/BL6J Mouse Model

Are gut dysbiosis, barrier disruption, and endotoxemia related to adipose tissue dysfunction in metabolic disorders? Overview of the mechanisms involved

Intestinal barrier disorders and metabolic endotoxemia in obesity: Current knowledge

Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids